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AVP inhibits EGF-stimulated MAP kinase cascade in Madin-Darby
canine kidney cells. We investigated the effects of epidermal growth factor
(EGF) and arginine vasopressin (AVP) on Raf-1-MAP kinase cascade,
including Raf-1-kinase (Raf-1-K), MAP kinase kinase (MAPKK), MAP
kinase (MAPK) and S6 kinase (S6K) in Madin-Darby canine kidney
(MDCK) cells. In a dose-dependent manner (10—10 M to 106 M), EGF
increased autophosphorylation of Raf-1-K and activated MAPKK, MAPK
and S6K. Sequential activation of these kinases was indicated by their peak
times of activation (Raf-1-K 5 mm; MAPKK 10 mm; MAPK 15 mm; and
S6K 30 mm). AVP (10 M to 10 M) inhibited EGF-stimulated MAP
kinase cascade. 8-Bromo-cyclic AMP (cAMP) could mimic the inhibitory
effect of AVP on EGF-stimulated MAP kinase cascade. These results
were confirmed using H-89, an inhibitor of protein kinase A (PKA) that
blocked the effect of AVP on EGF-stimulated MAPK activity. We
conclude that AVP inhibits EGF-stimulated Raf-1-K, MAPKK, MAPK,
and S6K activity via cAMP in MDCK cells. Our results indicate that MAP
kinase cascade may play an important role in integrating the effects of
AVP and EGF on distal tubule function.
Mitogen-activated protein kinases (MAPKs) are members of
serine/threonine kinases, which are activated by phosphorylation
on both threonine and tyrosine residues [1]. MAPKS play an
important role in mediating the signal transduction pathways
when quiescent cells are stimulated with many mitogenic agents
[2]. MAP kinase cascade is a protein kinase cascade, which
involves MAP kinase kinase kinase (c-Raf-1, MEKK) [3—6], MAP
kinase kinase (MAPKK) [7—9], and MAP kinase (MAPK).
The physiological functions of MAP kinase cascade have been
investigated in vascular smooth muscle cells and glomerular
mesangial cells [10, 111. However, this serine/threonine cascade
has not been well investigated in renal tuble cells. We and Itoh et
al showed that hyperosmolarity activated MAP kinase in Madin-
Darby canine kidney (MDCK) cells (a cell culture model of the
distal tubule) [12, 13]. Recently, Heasley et al investigated the
hormonal regulation of MAPK in cultured rat inner medullary
collecting tubule (RIMCT) cells [14]. They demonstrated that
MAPK serves as a convergence point for many signaling pathways
including receptor tyrosine kinase, G protein-coupled receptors,
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and protein kinase C in RIMCT cells [14]. These results suggested
that MAP kinase cascade might contribute to physiological events
in renal tubule cells.
Arginine vasopressin (AVP) is the principle hormone regulat-
ing water and electrolyte transport in the distal tubule [15, 16].
Epidermal growth factor (EGF) is also known to regulate cell
transport and to play an important role in cell proliferation and
differentiation in renal cells [17—20]. Although antagonism be-
tween AVP and EGF via water transport has been demonstrated
by Breyer, Jacobson and Breyer [19], interaction between AVP
and EGF via MAP kinase is not yet fully understood.
AVP is known to stimulate MAPK through protein kinase C
(PKC) in vascular smooth muscle cells [10]. However, the effect of
AVP on MAPK in renal epithelial cells has not yet been reported.
Recently, cyclic AMP (cAMP) has been reported to inhibit
EGF-stimulated MAP kinase cascade in Rat-i cells [21, 22]. Thus,
it is of great interest to examine whether EGF-stimulated MAP
kinase cascade is activated or inhibited after binding of AVP in
renal distal tubules, In this study, we investigated the effect of
AVP on EGF-stimulated MAP kinase cascade and [3H]-thymi-
dine incorporation in MDCK cells. We also evaluated the effects
of 8-bromo cAMP and protein kinase A (PKA) inhibitor, H-89, on
EGF-activated MAP kinase cascade in MDCK cells.
Methods
Cell culture and preparation of extracts
MDCK cells originally purchased from the American Type
Culture Collection (Rockville, MD, USA) were grown in a
defined medium comprising a 50:50 mixture of Dulbecco's mod-
ified Eagle's medium (DMEM) with 5 mM glucose and Coon's
modified Eagle's medium supplemented with 10 mrvi HEPES, 5
M triiodothyronine, 50 fLM hydrocortisone, 10 flM Na2SeO3,
transferrin at 5 .tWml, insulin at 5 Wml, prostaglandin E1 at 25
ng/ml, 2 mivi L-glutamine, penicillin at 50 IU/ml, and streptomycin
at 50 g/ml. MDCK cells were plated directly into 35 mm
multiwell dishes. At three to five days after plating, just before
reaching confluence, the medium was replaced with serum-free
medium overnight to prepare for the stimulation experiments.
EGF and AVP were added at indicated times and concentrations
at 37°C. After incubation, cells were scraped into a total volume of
0.5 ml of extraction buffer containing 50 mM f3-glycerophosphate
pH 7.3, 1.5 mrvi EGTA, 0.1 mrvi Na3VO4, 1 mrvi D'flT, 10 jkg/ml
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leupeptin, 10 .tg/ml aprotinin, 2 ig/ml pepstatin A, and 1 mM
benzamide. Cells in extraction buffer were sonicated for 20
seconds (Sonicator, Central Co., Tokyo, Japan), and centrifuged
at 100,000 X g for 20 minutes at 4°C (Beckman, TL-100 centri-
fuge, Palo Alto, CA, USA). Supernatants (0.3 mg/ml protein)
were stored frozen at —80°C.
Kinase assays
MAPK and S6K assays. MDCK cytosolic extracts (12.5 p1) were
mixed with 4 .tl of 0.33 mglml myelin basic protein (MBP) for
MAPK assay or 4 p1 of 1.8 mg/mi S6 peptide (RRRLSSLRA)
(UBI, Lake Placid, NY, USA) for S6K assay. Phosphorylation
reactions were initiated by adding 8.3 p1 of kinase assay buffer
containing 50 mrvt 3-glycerophosphate pH 7.3, 3.75 mivi EGTA,
0.15 mi DTT, 30 LM calmidizolium, 6 j.LM protein kinase inhibitor
(PM) peptide, 30 mivi MgC12, 0.1 mivi ATP, and 0.3 mivi [y-32P]
ATP (specific activity - 2000 cpm/pmol), and the mixture was
incubated at 30°C for 15 minutes. The reaction was terminated by
spotting 20 p1 of assay mixture onto P-81 phosphocellulose filter
paper (Wattman, Maidstone, UK). The paper was washed several
times with 175 m phosphoric acid, and radioactivity was counted.
In filter paper assays of kinase activity in cytosolic extracts, levels
of phosphate incorporation measured in the absence of substrate
were subtracted from the values measured in the presence of
substrate, to correct for nonspecific phosphorylation.
MAPKK assay. MDCK cytosolic extracts (12.5 p1) were mixed
with or without 5.2 p1 of 4.8 ig/ml MAPK protein (UBI), and
phosphorylation reactions were initiated by adding 8.3 pJ of the
kinase assay buffer described above without [y-32P] ATP. After
incubation at 30°C in 10 minutes, MBP phosphorylation was
initiated by adding 4 p1 of 0.33 mg/mi MBP and 0.3 mrvi [y-32P]
ATP (specific activity 2000 cpm/pmol), and the mixture was
incubated at 30°C for 15 minutes. The reaction was terminated by
spotting 20 p1 of assay mixture onto P-81 phosphocellulose filter
paper (Wattman). The paper was washed several times with 175
m phosphoric acid, and radioactivity was counted. To correct for
nonspecific phosphorylation, levels of phosphate incorporation
measured in the absence of exogenous MAPK protein were
subtracted from the values measured in the presence of exoge-
nous MAPK protein.
Raf-1-K autophosphoiylation
After varying incubation time at 37°C in medium containing
EGF or AVP at the indicated concentrations, cells were scraped
into a total volume of 0.5 ml of lysis buffer containing 10 mM
-glycerophosphate, pH 7.4, 1.0 mivi EDTA, 5.0 mivi EGTA, 0.15
mM Na3 V04, 2.0 mM DTT, 20 mivi HEPES, pH 7.4, 0.5% (vol/vol)
Nonidet P-40, 0.1% (wt/vol) sodium deoxycholate, 1 mM phenyl-
methylsulfonyl fluoride (PMSF), 10 .tg/ml aprotinin, 10 jig/mI
leupeptin. Lysates were allowed to remain on ice for 30 minutes,
and were centrifuged at 15,000 rpm for 30 minutes at 4°C.
Supernatants were incubated for two hours at 4°C with 3 jil of
rabbit anti-c-Raf-1-K antibody (UBI) and protein G-Sepharose,
and immune complexes were recovered by centrifugation. Pellets
were washed three times with the protein assay buffer described
above. The pellets were used in immune complex kinase assays as
described by Siegel et al [23, in 50 p1 volume of 10 mivi Tris-HCI
pH 7.5, 10 mivi MnCI2, 150 mivi NaCI, 10 mivi MgCl2, 2 mrvi DTT,
and 1.2 mivi [y-32P] ATP (specific activity — 2000 cpm/pmol), for
five minutes at 37°C. Reactions were terminated by adding 1%
SDS and boiling for five minutes. Then samples were resolved in
SDS-polyacrylamide electrophoresis gel, and phosphorylation of
Raf-1-K was detected by autoradiography.
cAMP measurement
After preincubation with serum-free DMEM for 24 hours and
incubation of confluent cells with AVP at the indicated concen-
trations for 15 minutes, cells were washed three times with
phosphate-buffered saline, pH 7.2, and extracted twice with 1.5 ml
of 10% trichloroacetic acid. Then the acid extracts were combined
and treated three times with 2 ml of water-saturated ether to
remove the acid. The extracts were then lyophilized and kept at
— 20°C. cAMP was measured after succinylation, using a radioim-
munoassay kit (Yamasa, Tokyo) containing a cAMP antiserum
and '251-labeled succinyl cAMP tyrosine methyl ester, as de-
scribed by Honma 24J.
[3H]-thymidine incoiporation
Confluent cells were trypsinized and plated in six-well plates in
DMEM containing 10% fetal calf serum. Two days after plating,
the medium was replaced with serum-free DMEM for 24 hours,
and then incubated for another 20 hours in the presence or
absence of EGF (10—8 M) with or without AVP (10—p M). Next,
cells were incubated for four hours with 0.5 jiCi of [3H]-thymi-
dine/well and radioactivity in TCA-precipitable material was
determined by liquid scintillation counting.
Statistics
The results were given as mean SEM. The differences were
tested using analysis of variance. P < 0.05 was considered
significant.
Results
Effects of EGF and AT/P on Raf-1-K autophosphotylation
To examine the effect of EGF on autophosphorylation of
Raf-1-K, MDCK cells were preincubated with EGF at 10— 10 M to
106 M for 10 minutes. Autophosphorylation was detected in
anti-c-Raf-1-K immunoprecipitants, incubated with [y-32Pj ATP.
Autophosphorylation of Raf-1-K by EGF stimulation was dose-
dependent (Fig. 1A). The effect of EGF on autophosphoiylation
reached its peak level at five minutes (data not shown). AVP
(10 M) inhibited EGF-stimulated autophosphorylation of Raf-
1-K (Fig. 1B).
Dose-dependence and time course of EGF-stimulated MAPKK
activity and the effect of A VP on EGF-stimulated MAPKK activity
MDCK cells were incubated in serum-free medium containing
EGF at final concentrations indicated for 10 minutes. EGF
increased MAPKK activity dose-dependently (10— 10 M to i07 M;
N = 5, mean snrvi; Fig. 2A). A total of 10—8 M and i0— M EGF
significantly increased MAPKK activity (Fig. 2A). Next, cells were
incubated with EGF (10 M) for the indicated periods. The effect
of EGF on MAPKK activity reached its peak level at 10 minutes
(N = 4, mean 5EM; Fig. 2B). We evaluated the effect of AVP on
EGF-stimulated MAPKK activity. AVP (10 M) significantly
inhibited EGF-stimulated MAPKK activity (N = 5, mean SEM;
Fig. 2A). This inhibitory effect of AVP on EGF-stimulated
MAPKK activity was dose-dependent (10 M to 10—6 M; N = 4,
mean SEM; Fig. 2C).




Fig. 1. Effects of EGF and Al/P on Raf-1-K autophosphoiylation. Auto-
phosphorylation was detected in anti-c-Raf-1-K immunoprecipitants, in-
cubated with y-32P] ATP. A. MDCK cells were incubated with various
concentrations (10'° M to 10 M) of EGF for 10 minutes. EGF
stimulated autophosphorylation of Raf-1-K dose-dependently. B. MDCK
cells were incubated with EGF (10—8 M) in the presence or absence of
AVP (10w M) for 10 minutes. AVP inhibited EGF-stimulated autophos-
phoiylation of Raf-1-K.
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Fig. 2. Dose-dependence and time course of EGF-stimulated MAPKK
activity and the effect 0fAVP on EGF-stimulated !vL4 PKK activity. A. MDCK
cells were incubated with various concentrations (10— 10 M to i07 M) of
EGF for 10 minutes. MAPKK activity was stimulated dose-dependently.
AVP (10 M) significantly inhibited EGF-stimulated MAPKK activity. B.
MDCK cells were incubated with EGF (10 M) for 5, 10, 15, 30, and 60
minutes. MAPKK activity reached its peak level at 10 minutes. C. The
inhibitoiy effect of AVP on EUF-stimulated MAPKK activity was dose-
dependent (10 M to 10_6 M). *p tP < 0.05.
genistein (2 X i0 M), inhibited EGF-stimulated MAPK activity
by 53.4 2.4% (N = 5, mean SEM; Fig. 4A). Treatment of cells



















































Dose-dependence and time course of EGF-stimulated MAPK
activity and the effects of genistein, caiphostin C, 8-Bromo-cAMP,
AVPand H-89 on EGF-stimulated MAPK activity
MDCK cells were incubated in serum-free medium contain-
ing EGF at the indicated concentrations for 15 minutes. EGF
increased MAPK activity dose-dependently (N = 5, mean
SEM; Fig. 3A). EGF at 10—8 M and io M significantly increased
MAPK activity (Fig. 3A). Next, cells were incubated with EGF
(10 M) for the indicated times. The effect of EGF on MAPK
activity reached its peak level at 15 minutes (N = 5, mean
SEM; Fig. 3B). Treatment of cells with tyrosine kinase inhibitor,
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Fig. 3. Dose-dependent curve and time course of EGF-stimulated MAPK
activity and the effect of A VP on EGF-stimulated MAPK activity. A. MDCK
cells were incubated with various concentrations (10—H) M to iO M of
EGF, and MAPK activity was stimulated dose-dependently. AVP (10— M)
significantly inhibited EGF-stimulated MAPK activity. B. MDCK cells
were incubated with EGF (10 M) for 5, 10, 15, 30, and 60 minutes.
MAPK activity reached its peak level at 15 minutes. C. The inhibitory
effect of AVP on EGF-stimulated MAPK activity was dose-dependent
(10 M to 106 M). AVP (10—6 M) alone also inhibited MAPK activity
compared to the control level. *p rP < 0.05.
significantly inhibit EGF-stimulated MAPK activity (N = 4, mean
SEM; Fig. 4A). Next, we evaluated the effect of AVP on
EGF-stimulated MAPK activity. AVP (i0 M) significantly in-
hibited EGF-stimulated MAPK activity (N = 5, mean SEM; Fig.
3A). This inhibitory effect of AVP on EGF-stimulated MAPK
activity was dose-dependent (N = 4, mean SEM; Fig. 3C). AVP
(106 M) alone also inhibited MAPK activity by 18.8 4.5%
compared to the control level (N = 4, mean SEM; Fig. 3C).
8-Bromo-cAMP (10 M) was able to mimic the inhibitory effect
of AVP on EGF-stimulated MAPK activity by 45.2 1.8% (N =
5, mean 5EM; Fig. 4A). PKA inhibitor, H-89, blocked the
inhibitory effect of AVP on EGF-stimulated MAPK activity (N =
4, mean sEM; Fig. 4B). H-89 alone had no significant effect on
EGF-stimulated MAPK activity (N = 4, mean SEM; Fig. 4B).
Furthermore, no significant difference was shown between EGF/
AVP/H-89 and EGF alone (Fig. 4B).
Dose-dependence and time course of EGF-stimulated S6K activily
and the effect of AVP on EGF-stimulated S6K activity
MDCK cells were incubated in serum-free medium containing
EGF at the indicated concentrations for 30 minutes. EGF signif-
icantly increased S6K activity dose-dependently (10— 10 M to
iO M; N = 5, mean SEM; Fig. 5A). Next, cells were incubated
with EGF (10 M) for the indicated times. The effect of EGF on
S6K activity reached its peak level at 30 minutes (N = 4, mean
5EM; Fig. SB). We evaluated the effect of AVP on EGF-stimulated
S6K activity. AVP (10 M) inhibited EGF (10—8 M) stimulated
S6K activity by 75.8 0.6% (N = 5, mean SEM; Fig. SC).
A VP-stimulated cAMP accumulation in MDCK cells
We measured cAMP accumulation in MDCK cells when AVP
was added. AVP increased cAMP accumulation dose-dependently
(10b0 M to 10—6 M) in MDCK cells (N = 4, mean SEM; Fig. 6).
EGF-stimulated [3H]-thymidine incorporation and the effect of
AVP on EGF-stimulated [3H]-thymidine incorporation
We evaluated the effects of AVP and EGF on [3H]-thymidine
incorporation in MDCK cells. EGF (10—8 M) increased [3H]-
thymidine incorporation, and AVP (10 M) significantly inhibited
EGF-stimulated [3H]-thymidine incorporation by 46.3 0.8%
(N = 5, mean SEM; Fig. 7).
Discussion
In the present study, we demonstrated EGF-induced sequential
activation of MAP kinase cascade and AVP inhibition of EGF-
stimulated MAP kinase cascade in MDCK cells.
MAPKs are activated in response to various mitogens, growth
factors, oncogene products, and several vasoactive peptide hor-
mones [25—28]. MAPK is phosphorylated and activated by MAP
kinase kinase (MAPKK or MEK), and MAPKK can be phosphor-
ylated and activated by Raf-1-K or MEK kinase (MEKK). Acti-
vation of these protein kinases induces phosphorylation of the
transcription factors c-Myc [29], c-Jun [30], and c-Fos [31], and
activates the protein-serine/threonine kinase S6K [32]. Activation
of Raf-1-MAP kinase cascade is a key event in mitogenic signal-
ing. Activation and regulation of this protein kinase cascade have
been investigated in vascular smooth muscle cells, glonierular
mesangial cells, and rat inner medullary collecting tubule
(RIMCT) cells [10, 11, 14]. Although hormonal regulation of
MAPK has been investigated in RIMCT cells by Heasley et al
[14], little is known about a role of MAP kinase cascade in renal
tubular cells.
In the present study, we demonstrated that EGF induces
activation of MAP kinase cascade in MDCK cells, including
Raf-1-K, MAPKK, MAPK, and S6K. Sequential activation is
A
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indicated by their peak times of activation (Raf-1-K 5 mm;
MAPKK 10 mm; MAPK 15 mm; and S6K 30 mm). In our data,
MAPK activity is inhibited by a tyrosine kinase inhibitor,
genistein. Conversely, the protein kinase C inhibitor, caiphostin C,
does not significantly inhibit MAPK activity. These data suggest
that MAP kinase cascade is stimulated mainly by receptor-
tyrosine kinase-dependent pathway in MDCK cells.
AVP plays an important role in regulating water and electrolyte
transport in distal tubules. Binding of AVP to V2 receptor induces
activation of adenylate cyclase. This results in generation of
cAMP, which in turn activates protein kinase A [331- cAMP has
been known as a modulator of cell proliferation in many cell types.
The effect of cAMP on cell growth is controversial. Agents that
increase intracellular cAMP stimulate proliferation of Swiss 3T3
cells [34]. Conversely, these same agents inhibit proliferation of
normal fibroblasts [35—40]. Recently, cAMP has been reported to
inhibit MAP kinase cascade [21, 22, 41]. Thus, in considering
physiological roles of MAPK in renal epithelial cells, it is of
interest to examine whether AVP inhibits MAP kinase cascade by
increasing intracellular cAMP in MDCK cells.
EGF is mitogenic for renal tubular cells [17, 18] and may also
regulate renal tubular transport [19, 20]. Thus, it is of great
interest to investigate how AVP and EUF regulate MAP kinase
cascade in distal tubules.
Our results demonstrate that AVP inhibits EGF-stimulated
MAP kinase cascade in MDCK cells. 8-Bromo-cAMP mimics the
inhibitory effect of AVP on MAP kinase cascade. The inhibitiory
effect of AVP was blocked by PKA inhibitor, H-89. Thus, we
conclude that AVP increases intracellular cAMP, which in turn
activates PKA and inhibits MAP kinase cascade in MDCK cells.
The effect of AVP on MAPK has already been investigated in
vascular smooth muscle cells (VSMCs) and RIMCT cells [10, 14,
38]. AVP activates MAPK by stimulating tyrosine phosphoryla-
tion in rat VSMCs [38]. Kribben et al demonstrated AVP-induced
activation of MAPK in VSMCs via protein kinase C [10]. Heasley
et al demonstrated that AVP does not significantly stimulate
MAPK activity in RIMCT cells [14]. Our results show that AVP
inhibits EGF-stimulated MAP kinase cascade in MDCK cells by
increasing intracellular cAMP. To our knowledge, our report is
the first demonstration that AVP inhibits MAPK activity. We
believe that these stimulatory and inhibitory effects of AVP derive
Fig. 4. Effects of genistein, 8-Br-cAMP,
caiphostin C, and H-89 on EGF-stimulated
MAPK activity. A. MDCK cells were incubated
with EGF (10_8 M) in the presence or
absence of either a tyrosine kinase inhibitor,
genistein (2 X i0 M), protein kinase C
inhibitor, calphostin C (10—6 M), or 8-Br-
cAMP (10 M) for 15 minutes. Treatment of
cells with genistein inhibited EGF-stimulated
MAPK activity. 8-Br-cAMP also inhibited
EGF-stimulated MAPK activity. Treatment of
cells with calphostin C did not significantly
inhibit EGF-stimulated MAPK activity. B.
Cells were incubated with EUF (10—8 M) and
AVP (10- M) in the presence or absence of
PKA inhibitor, H-89 (10 M) for 15 minutes.
H-89 blocked the inhibitory effect of AVP on
EGF-stimulated MAPK activity. H-89 alone
had no significant effect on EGF-stimulated
MAPK activity. *P < 0.05.
from differential localization of V1 and V2 receptors among
VSMCs and renal tubular cells, Although V1 receptor localizes in
many tissues including VSCMs [39], the expression of V2 receptor
is reported only in renal cells [40].
Recently, cAMP has been reported to inhibit MAP kinase
cascade [21, 22]. It has been reported that there is an antagonism
between PKA and MAP kinase cascade [41]. The mechanism by
which cAMP and PKA inhibit MAP kinase cascade is not clear.
Simon and Frank demonstrated that cAMP inhibits the signal
transduction from Ras by preventing Ras-dependent activation of
Raf-1-K [21]. Hordijk et al also showed that cAMP abrogates
MAP kinase cascade at a step downstream of Ras activation [22].
In the present study, we have shown that AVP inhibits EGF-
stimulated Raf-1-K autophosphorylation. Although we did not
evaluate Ras activity in this study, the inhibitory effect of AVP
seems to derive from prevention of Ras-dependent activation of
Raf-1-K. Thus, AVP and EGF may cross-talk through MAP
kinase cascade via Ras-activated Raf-1-K in MDCK cells.
The physiological functions of this cross-talking have not yet
been clarified. One possibility is that AVP inhibits EGF-induced
cell proliferation in MDCK cells. Rodrig et al examined the
correlation between intracellular cAMP levels and dome forma-
tion when AVP was added to MDCK cells [42]. They showed that
time course and the levels of dome formation do not correlate
with those of cAMP elevation. In their paper, they reported that
the elevation of intracellular cAMP preceded dome formation.
We believe that their data indicate the inhibitory effect of AVP on
mitogenic response in MDCK cells. Our hypothesis is that AVP
inhibits mitogenic response by decreasing MAP kinase cascade
activity in MDCK cells. Hordijk et al demonstrated inhibition of
EGF-induced [3H]-thymidine incorporation by cAMP in Rat-I
fibroblasts [22]. Thus, we examined the effect of AVP on
thymidine incorporation in MDCK cells. We showed that AVP
inhibits EGF-stimulated [3H]-thymidine incorporation in MDCK
cells. This result is compatible with our hypothesis that AVP
inhibits mitogenic signaling in MDCK cells.
Breyer et al examined the effect of EGF on AVP-stimulated
hydraulic conductivity [19]. They demonstrated an inhibitory
effect of EGF on AVP-stimulated water flow in isolated perfused
rabbit cortical collecting tubules. Although the relationship be-
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A Fig. 5. Dose-dependent curve and time course of EGF-stimulated S6K
7011
activity and the effect of AVP on EGF-stimulated S6K activity. A. MDCK
cells were incubated with various concentrations (10w M to i0 M) of
EGF for 30 minutes. EGF stimulated S6K activity dose-dependently. H.
600 Cells were incubated with EGF (10—v M) for 5, 10, 15, 20, 30, and 60
minutes. S6K activity reached its peak level at 30 minutes. C. Cells were
incubated with EGF (10_s M) in the presence or absence of AVP (10 M)
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200 Fig. 6. A VP-stimulated cAMP accumulation in MDCK cells. MDCK cells
were incubated with various concentrations (10—10 M tO 106 M) of AVP
100 for 15 minutes. AVP increased cAMP accumulation dose-dependently.
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clear, their work is interesting from the standpoint of the cross-
C talk between EGF and AVP via water transport in renal tubules.
In the present study, our results represent the first demonstration
of cross-talk between EGF and AVP via MAP kinase cascade in
240 MDCK cells. Further experiments will be required to clarify the
______
relationship between MAP kinase cascade and renal tuble trans-
ports.
—. 200 In conclusion, AVP inhibits EGF-stimulated Raf-1-K,
. MAPKK, MAPK, and S6K activity via cAMP in MDCK cells. Our
results indicate that MAP kinase cascade may play an important
(I) '-. role in integrating the effects of EGF and AVP on distal tubule
160 function.
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